"rationale","uuid:ID","versionIdentifier","instanceType","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","aa5d22aa-3fa1-47d9-9e16-866d4a560b82","2","StudyVersion","StudyVersion_1"
